Aareleid T, Sant M, Hédelin G
Department of Epidemiology and Biostatistics, Institute of Experimental and Clinical Medicine, Tallinn, Estonia.
Eur J Cancer. 1998 Dec;34(14 Spec No):2236-40. doi: 10.1016/s0959-8049(98)00313-x.
Within the framework of EUROCARE, a population-based study on survival and care of cancer patients in Europe, we analysed survival of 7426 men with testicular cancer diagnosed between 1985 and 1989 in 17 countries. For comparison between the countries, survival rates were age-standardised to the age structure of the entire study population. Among the participating countries of Northern, Western, Central and Southern Europe and the U.K., the age-standardised 5-year relative survival rate varied from 89% (Finland) to 93% (Spain, Germany). In Eastern Europe, the rate ranged from 48% (Estonia) to 84% (Slovenia). Rates in Poland, Slovakia and Estonia were significantly lower than the summary rate for Europe (P < 0.05). Relative survival generally decreased with the age of patients at diagnosis. Based on the weighted analysis of pooled European data, the 5-year relative survival rate was 91% for patients aged 15-44 years; 85% for patients aged 55-64 years; and 59% for patients aged 75 years and over. The time trend in survival by 3-year periods between 1978 and 1989 was studied on the basis of 12,084 cases provided by 12 countries. From 1978-1980 to 1987-1989, the 5-year relative survival rate for Europe increased from 79 to 93% (P < 0.05). The inequalities in survival between the more developed European countries were more notable in the 1970s than in the 1980s, suggesting that the treatment for testicular cancer became standardised in the latter period. Poorer survival in Eastern Europe and particularly in Estonia, could be related to later introduction of the effective cytotoxic treatments, but also to longer diagnostic delay and limited availability of modern staging procedures.
在欧洲癌症患者生存与护理的基于人群的研究EUROCARE框架内，我们分析了1985年至1989年间在17个国家诊断出的7426例睾丸癌男性患者的生存情况。为便于各国之间进行比较，生存率按整个研究人群的年龄结构进行了年龄标准化。在北欧、西欧、中欧、南欧的参与国以及英国中，年龄标准化的5年相对生存率从89%（芬兰）到93%（西班牙、德国）不等。在东欧，该比率从48%（爱沙尼亚）到84%（斯洛文尼亚）不等。波兰、斯洛伐克和爱沙尼亚的比率显著低于欧洲的汇总比率（P<0.05）。相对生存率通常随着诊断时患者年龄的增加而降低。基于对汇总的欧洲数据的加权分析，15 - 44岁患者的5年相对生存率为91%；55 - 64岁患者为85%；75岁及以上患者为59%。基于12个国家提供的12084例病例，研究了1978年至1989年期间每3年的生存时间趋势。从1978 - 1980年到1987 - 1989年，欧洲的5年相对生存率从79%提高到93%（P<0.05）。欧洲较发达国家之间的生存不平等在20世纪70年代比在80年代更显著，这表明睾丸癌治疗在后期变得标准化。东欧尤其是爱沙尼亚生存率较低，可能与有效细胞毒性治疗引入较晚有关，但也与诊断延迟较长以及现代分期程序的可及性有限有关。
